PVI
BEAM icon

Pura Vida Investments’s Beam Therapeutics BEAM Stock Holding History

Pura Vida Investments’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$5.73M – 216
2022
Q1 		$5.73M Buy
+100,000
New +$6.56M 0.19% 113

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Pura Vida Investments's BEAM Position: Q1 2022 in Review

Pura Vida Investments sold out of Beam Therapeutics (BEAM) in Q1 2022, closing a stake of 13,978 shares — an estimated $917K sold.

Pura Vida Investments first reported a position in BEAM in Q2 2021 and held it in 3 quarters. The position peaked at $3.22M in Q2 2021. 240 funds tracked by Wall St. Rank hold BEAM as of Q1 2022.

  • Pura Vida Investments reported no remaining Beam Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 13,978 Beam Therapeutics shares in Q1 2022, an estimated $917K.
  • Pura Vida Investments first reported a position in Beam Therapeutics in Q2 2021 and held it in 3 quarters.
  • Pura Vida Investments's Beam Therapeutics position peaked at $3.22M in Q2 2021.
  • 240 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.